Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
Introduction: Phase 1b GO30140 and phase 3 IMbrave150 studies evaluated first-line atezolizumab + bevacizumab for unresectable hepatocellular carcinoma (HCC). Here, we evaluated pharmacokinetics (PK) and safety by hepatic impairment status and geographic region. Methods: Patients received atezolizum...
Main Authors: | Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno, Benjamin Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2021-06-01
|
Series: | Liver Cancer |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/515817 |
Similar Items
-
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
by: Hideki Iwamoto, et al.
Published: (2021-06-01) -
Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
by: Ali AL Zahrani, et al.
Published: (2021-03-01) -
Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
by: Colby S. Shemesh, et al.
Published: (2020-12-01) -
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance
by: Yulei Wang, et al.
Published: (2021-08-01) -
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01)